Studying a new injection for moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had moderate to severe eczema for at least 1 year.
- Your eczema has not responded well enough to prescription creams (like corticosteroids or topical calcineurin inhibitors).
- You are willing to use a plain moisturizer twice daily for at least 7 days before the study starts.
- You are able to attend clinic visits and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new stem cell injection called ADSTEM for people with moderate to severe eczema that hasn't improved with standard treatments. The goal is to see if it can reduce eczema symptoms like itching, redness, and skin rash.
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.